Lynne Nardizzi, LICSW

Street Address

City, State, Zip

415-342-6717

psychotherapy, support and integration for spiritual experiences

PSYCHOTHERAPY FOR ADOLESCENTS, CHildren AND ADULTS

Lynne Nardizzi, LICSW

Blog

LSD, Psychosis and Healing

May 18, 2023 Lynne Nardizzi

This study explores the paradoxical relationship connecting key parameters of the psychotic experience, psychotherapy, and psychedelic experience.

The link between psychosis model and therapeutic model seems to lie in mystical experiences.

The results point to the importance of meaning attribution for the LSD psychosis model and indicate that psychedelic-assisted therapy might benefit from therapeutic suggestions fostering mystical experiences.

Ketamine for Adolescents?

May 17, 2023 Lynne Nardizzi

This ketamine study looks at four adolescent cases (aged 14–19), each with a variety of comorbid diagnoses including treatment-resistant depression, bipolar disorder, eating disorders, anxiety, panic, and trauma-related symptoms.

Their courses varied, but each had symptomatic and functional improvements, and the ketamine treatment was well-tolerated.

Brain Activity During Dying

May 6, 2023 Lynne Nardizzi

A new study hints at how consciousness can continue after the heart stops. A burst of brain activity during dying could explain life passing before your eyes.

Psilocybin Therapy for Cancer and Depression

April 20, 2023 Lynne Nardizzi

New research shows that cancer patients experienced clinically meaningful, rapid, and sustained improvement in symptoms of depression over 8 weeks following a single treatment of psilocybin therapy.

This occurred in patients with both curable and metastatic cancer.

Ibogaine Update

April 15, 2023 Lynne Nardizzi

Will ibogaine fit into the medicalized psychedelic landscape?

Microdosing, Setting, and Does it Work?

April 14, 2023 Lynne Nardizzi

The research on benefits and long-term effects of microdosing continues to be mixed.

Update: MDMA-Assisted Therapy for Treatment of PTSD

April 9, 2023 Lynne Nardizzi

MAPS PBC announces positive topline results from long-term observational follow-up study on MDMA-assisted therapy for treatment of PTSD.

Interim results show improvements in PTSD symptom severity lasted at least six months after the last treatment session.

Findings are consistent with previously published Phase 2 data[1] on the sustained effect of MDMA-assisted therapy for the treatment of PTSD.

A Non-Hallucinogenic LSD Analog?

March 17, 2023 Lynne Nardizzi

BetterLife Pharma Inc., an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announced that findings from a study on its lead candidate BETR-001 (2-bromo-LSD) titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders” has been published in the peer-reviewed journal of Cell Report.

What do you think?